A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

Source:http://linkedlifedata.com/resource/pubmed/id/20960521

Cancer 2011 Mar 15 117 6 1253-61

Download in:

View as

Triples

General Info

PMID
20960521